TWO PTS UNDERGO LIVER ALLOTRANSPLANTATION (OLTX) FOLLOWING EXTRACORPOREAL HEPATIC SUPPORT WITH TRANSGENIC (hCD55/hCD59) PORCINE LIVERS: CLINICAL RESULTS AND LACK OF PIG TO HUMAN TRANSMISSION OF THE PORCINE ENDOGENOUS RETROVIRUS (PoERV).

Lévy, M; Crippin, Jeffrey S.; Sutton, Steven W.; Netto, George; Jung, G J; Molmenti, Ernesto P.; GOLDSTEIN, R.; Gonwa, Thomas A.; Logan, John S.; Klintmalm, Göran B.

doi:10.1097/00007890-199905150-00237

Cited by 38 publications

(61 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…No evidence of PERV infection has been found in nonhuman primates (21) or human patients exposed to porcine tissues including pig islet xenotransplantation, extracorporeal splenic or kidney perfusion (18,(22)(23)(24)(25). We have published that a range of nonhuman primate cell lines have two different blocks to productive infection, one at the level of viral entry and the other a defect in viral particle assembly (26).…”

Section: Introductionmentioning

confidence: 99%

Pseudotyping of Porcine Endogenous Retrovirus by Xenotropic Murine Leukemia Virus in a Pig Islet Xenotransplantation Model

Martina

Kurian

Cherqui

et al. 2005

American Journal of Transplantation

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Pseudotyping of Porcine Endogenous Retrovirus by Xenotropic Murine Leukemia Virus in a Pig Islet Xenotransplantation Model

Martina

Kurian

Cherqui

et al. 2005

American Journal of Transplantation

View full text Add to dashboard Cite

show abstract

“…No evidence of PERV infection was seen despite the finding of prolonged pig cell microchimerism in some of the recipients. Other studies in 13 recipients of embryonic porcine mesencephalic tissue or extracorporeal perfusion with transgenic pig livers also found no evidence of PERV sequences by polymerase chain reaction testing peripheral blood mononuclear cells [72,73]. More recently, evidence has been provided of lack of cross-species transmission of PERV infection to 23 nonhuman primates exposed to vascularized porcine organs or tissue xenografts, given immunosuppressive agents in some animals [74].…”

Section: The Risk Of Infectionsmentioning

confidence: 99%

Xenotransplantation in the 21st Century

Perico¹,

Benigni²

2002

Blood Purif

View full text Add to dashboard Cite

Xenotransplantation, i.e. transplantation across species, is increasingly being viewed a potential solution to the problem of severe shortage of transplant donors. Clinical application of xenotransplantation is, however, limited in large part by the pre-eminent hurdle of the immune response of the recipient against the graft. This immunologic reaction is mediated initially by natural xenoreactive antibodies, complement and natural killer cells, and later by elicited humoral and cellular immune responses that ultimately lead to graft failure. Progress in understanding the cellular and molecular basis of xenograft rejection has characterized the past few years. Additional hurdles to xenotransplantation include physiologic incompatibility of the transplant and the risk of infections. The recent development of novel strategies to overcome xenograft rejection has brought about great optimism that xenotransplantation may be attainable in the near future.

show abstract

“…Levi et al reported the first two cases of ECLP using transgenic porcine livers to overcome a potential immunologic barrier (hCD55/hCD59), and both were successfully bridged to liver transplantation. 23 Xu et al performed a clinical trial of extracorporeal perfusion treatment using transgenic whole porcine liver in two patients, and reported no symptoms of porcine endogenous retrovirus (PERV) infection. 24 …”

Section: Extracorporeal Whole Liver Perfusion (Eclp)mentioning

confidence: 99%

“…Cross-hemodialysis system using four living dogs (Hori et al15 ) Extracorporeal liver perfusion systems (Neuhaus et al23 )…”

mentioning

confidence: 99%

Development and Perspectives of Perfusion Treatment for Liver Failure

et al. 2005

View full text Add to dashboard Cite

To treat patients with severe liver failure, liver transplantation and blood purification therapy, including plasmapheresis, hemodiafiltration, and bioartificial liver support, are available. The two mainstream systems developed for bioartificial liver support are extracorporeal whole liver perfusion (ECLP) and the bioreactor system (BIS). We developed a method of cross-plasma perfusion, in which plasma is exchanged between the blood circuit of the patient and that of a hepatic functioning unit, through which immunologically free whole human blood is perfused. From the aspects of efficacy and epidemic safety, the best system of bioartificial liver support for clinical use is considered to be ECLP in cross-plasma perfusion. In opposition, a social antagonist for zoonosis has consistently been raised, with controversy surrounding the use of xenogeneic organs for human treatment, which might be final obstacle. It is possible that the combination therapy of hemodiafiltration and the administration of human serum albumin and anticoagulant factors, which minimizes the economic and medical resource costs through the development of transgenic livestock that secrete human pharmaceuticals systemically, will become a more desirable and practical treatment for patients with severe liver failure.

show abstract

TWO PTS UNDERGO LIVER ALLOTRANSPLANTATION (OLTX) FOLLOWING EXTRACORPOREAL HEPATIC SUPPORT WITH TRANSGENIC (hCD55/hCD59) PORCINE LIVERS: CLINICAL RESULTS AND LACK OF PIG TO HUMAN TRANSMISSION OF THE PORCINE ENDOGENOUS RETROVIRUS (PoERV).

Cited by 38 publications

References 0 publications

Pseudotyping of Porcine Endogenous Retrovirus by Xenotropic Murine Leukemia Virus in a Pig Islet Xenotransplantation Model

Pseudotyping of Porcine Endogenous Retrovirus by Xenotropic Murine Leukemia Virus in a Pig Islet Xenotransplantation Model

Xenotransplantation in the 21st Century

Development and Perspectives of Perfusion Treatment for Liver Failure

Contact Info

Product

Resources

About